Carl Zeiss Meditec AG: Carl Zeiss Meditec clearly on growth course

Carl Zeiss Meditec AG / Carl Zeiss Meditec clearly on growth course processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Revenue in the first nine months of financial year 2009/2010 increases to EUR 490.8 million - positive outlook for the year confirmed

 

JENA - 12 August 2010.
With a 20 percent increase in revenue in the third quarter compared with the same quarter of the previous year, Carl Zeiss Meditec generated a very solid result and is thus clearly on a growth course. The Company grew by a total of 3 percent in the first nine months of financial year 2009/2010, to EUR 490.8 million (previous year: EUR 478.5 million) and increased its gross margin by 1.7 percentage points year-on-year, to 52.1 percent. Earnings before interest and tax rose by 11.8 percent to EUR 60.0 million; the EBIT margin increased to 12.2 percent (previous year: 11.2 percent).

 

"We did all our homework during the times of global economic crisis - for us, this also included continuing to strategically invest in our innovative strength. This policy is now paying off - which is clear not only from our figures today," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

 

Regionally, the Company is benefiting from more stable markets overall. With almost 10 percent, the "Asia/Pacific" region continues to be the growth driver. The "Americas" region is being stimulated by a growing demand in the USA - the Company's largest market. "Europe, Middle East and Africa" is the only region where perceptible uncertainties persist; however, these uncertainties were significantly overcompensated by the other two regions.

 

On the level of the strategic business units, the "Surgical Ophthalmology" SBU once again proved its high future potential, growing by 6 percent compared with the first nine months of 2008/2009. The "Microsurgery" SBU also grew by around 6 percent, while the "Ophthalmic Systems" SBU showed stable development. 

 

"Given our successful development, particularly in the third quarter, we anticipate total revenue for financial year 2009/2010 of between EUR 660 million and EUR 670 million. We are aiming to increase our EBIT margin by around 40 base points compared with the previous year," says Dr. Ludwin Monz. "We already laid the foundations for profitable growth in 2008 with our corporate programme, RACE 2010. This has clearly paid off. We are more than confident that we will be able to stay on this successful track and accelerate our growth with the successor programme due to start in the coming financial year."

Revenue by strategic business unit

Figures in EUR '000	9 Months 2008/2009	9 Months 2009/2010	Change from previous year
Ophthalmic Systems	232,238	231,660	-0.2%
Surgical Ophthalmology	61,566	65,039	+5.6%
Microsurgery	184,730	194,132	+5.1%

 

Revenue by region

Figures in EUR '000	9 Months 2008/2009	9 Months 2009/2010	Change from previous year
EMEA	184,590	181,296	-1.8%
Americas	165,733	168,964	+1.9%*)
Asia/Pacific	128,211	140,571	+9.6%

*) currency-adjusted: +5.4%

 

 

Contact:

Eva Sesselmann Director Group Communications Carl Zeiss Meditec AG Göschwitzer Straße 51-52 07745 Jena Phone: [phone] Fax: [phone] E-mail: [e-mail] (mailto:[e-mail])

Patrick Kofler Director Investor Relations Carl Zeiss Meditec AG Göschwitzer Straße 51-52 07745 Jena Phone: [phone] Fax: [phone] E-mail: [e-mail] (mailto:[e-mail])

 

HUG#1437392

--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN: 531370;ISIN: DE0005313704;Index:TecDAX,Prime All Share,TECH All Share;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;